

Triple-negative breast cancer: is there a treatment on th

Oncotarget

8, 1913-1924

DOI: [10.18632/oncotarget.12284](https://doi.org/10.18632/oncotarget.12284)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 835-847.	6.1	52
2	Identification of Breast Cancer Inhibitors Specific for G-protein-Coupled Estrogen Receptor (GPER)-Expressing Cells. <i>ChemMedChem</i> , 2017, 12, 1279-1285.	3.2	47
3	Clinical outcome of brain metastases differs significantly among breast cancer subtypes. <i>Oncology Letters</i> , 2017, 14, 194-200.	1.8	25
4	Small-molecule RL71-triggered excessive autophagic cell death as a potential therapeutic strategy in triple-negative breast cancer. <i>Cell Death and Disease</i> , 2017, 8, e3049-e3049.	6.3	25
5	The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. <i>Disease Markers</i> , 2017, 2017, 1-14.	1.3	18
6	P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. <i>PLoS ONE</i> , 2017, 12, e0172324.	2.5	60
7	PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. <i>International Journal of Oncology</i> , 2018, 52, 755-767.	3.3	15
8	YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 687-695.	2.3	18
9	Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 7022-7030.	8.0	23
10	MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. <i>Cell Death and Disease</i> , 2018, 9, 14.	6.3	124
11	Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling. <i>Biomedicine and Pharmacotherapy</i> , 2018, 103, 435-442.	5.6	12
12	Expression and prognostic significance of ECT2 in invasive breast cancer. <i>Journal of Clinical Pathology</i> , 2018, 71, 442-445.	2.0	48
13	Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. <i>Journal of Surgical Research</i> , 2018, 222, 93-101.	1.6	87
14	Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. <i>Journal of Immunotherapy</i> , 2018, 41, 64-72.	2.4	29
15	Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2018, 18, 629-639.	1.6	10
16	LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers. <i>Oncotarget</i> , 2018, 9, 22586-22604.	1.8	21
17	Actionable Gene Alterations in an Asian Population With Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	3.0	3
18	Implications of nestin in breast cancer pathogenesis (Review). <i>International Journal of Oncology</i> , 2018, 53, 477-487.	3.3	6

#	ARTICLE	IF	CITATIONS
19	Knockdown of nucleophosmin 1 suppresses proliferation of triple-negative breast cancer cells through activating CDH1/Skp2/p27kip1 pathway. <i>Cancer Management and Research</i> , 2019, Volume 11, 143-156.	1.9	19
20	RASEF expression correlates with hormone receptor status in breast cancer. <i>Oncology Letters</i> , 2018, 16, 7223-7230.	1.8	3
21	Eribulin Treatment Induces High Expression of miR-195 and Inactivates the Wnt/ β -catenin Signaling Pathway in Triple-negative Breast Cancer. <i>The Showa University Journal of Medical Sciences</i> , 2018, 30, 359-370.	0.1	0
22	The Yin and Yang of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers. <i>Cancers</i> , 2018, 10, 346.	3.7	75
23	Nucleolar stress: is there a reverse version?. <i>Journal of Cancer</i> , 2018, 9, 3723-3727.	2.5	11
24	Antitumor activity of NAX060: A novel semisynthetic berberine derivative in breast cancer cells. <i>BioFactors</i> , 2018, 44, 443-452.	5.4	13
25	SOX2 Promotes Cell Proliferation and Metastasis in Triple Negative Breast Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 942.	3.5	59
26	Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 339-351.	2.5	11
27	Integration of Ca ²⁺ signaling regulates the breast tumor cell response to simvastatin and doxorubicin. <i>Oncogene</i> , 2018, 37, 4979-4993.	5.9	29
28	Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway. <i>International Journal of Oncology</i> , 2018, 52, 1727-1737.	3.3	45
29	Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing <i>p15</i> , <i>INK4B</i> , <i>p16</i> , <i>INK4A</i> , and <i>p57</i> transcription. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 897-904.	2.0	21
30	β -amino alcohols and their respective 2-phenyl-N-alkyl aziridines as potential DNA minor groove binders. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 657-664.	5.5	16
31	<i>Annona muricata</i> Leaf Extract Triggered Intrinsic Apoptotic Pathway to Attenuate Cancerous Features of Triple Negative Breast Cancer MDA-MB-231 Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-10.	1.2	25
32	(α)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer. <i>Molecules</i> , 2018, 23, 1160.	3.8	37
33	B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer. <i>Cancer Cell International</i> , 2018, 18, 100.	4.1	28
34	Cellular and Animal Model Studies on the Growth Inhibitory Effects of Polyamine Analogues on Breast Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 24.	2.9	12
35	Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. <i>Clinical Drug Investigation</i> , 2018, 38, 639-648.	2.2	20
36	To Evaluate the Incidence of ER, PR and Her2/Neu Status in Newly Diagnosed Breast Cancer Patients at a Tertiary Care Centre. <i>Indian Journal of Gynecologic Oncology</i> , 2018, 16, 1.	0.3	0

#	ARTICLE	IF	CITATIONS
37	nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. <i>Annals of Oncology</i> , 2018, 29, 1763-1770.	1.2	94
38	A novel 1,4-naphthoquinone-derived compound induces apoptotic cell death in breast cancer cells. <i>Turkish Journal of Biology</i> , 2019, 43, 256-263.	0.8	10
39	Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles. <i>Scientific Reports</i> , 2019, 9, 11632.	3.3	20
40	The Anticancer and Antioxidant Effects of Muscadine Grape Extracts on Racially Different Triple-negative Breast Cancer Cells. <i>Anticancer Research</i> , 2019, 39, 4043-4053.	1.1	27
41	Inhibition of DNA Repair Mechanisms and Induction of Apoptosis in Triple Negative Breast Cancer Cells Expressing the Human Herpesvirus 6 U94. <i>Cancers</i> , 2019, 11, 1006.	3.7	13
42	EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers. <i>International Journal of Pharmaceutics</i> , 2019, 569, 118605.	5.2	28
43	Recent advances in nanotheranostics for triple negative breast cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 430.	8.6	121
44	Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1068.	2.8	43
45	Promyelocytic Leukemia (PML) gene regulation: implication towards curbing oncogenesis. <i>Cell Death and Disease</i> , 2019, 10, 656.	6.3	12
46	Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion. <i>Frontiers in Oncology</i> , 2019, 9, 1074.	2.8	15
47	Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells. <i>Cancers</i> , 2019, 11, 105.	3.7	26
48	RLIP inhibition suppresses breast-to-lung metastasis. <i>Cancer Letters</i> , 2019, 447, 24-32.	7.2	16
49	Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 1093-1099.	5.2	32
50	Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis. <i>PLoS ONE</i> , 2019, 14, e0218030.	2.5	15
51	Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain. <i>Drugs</i> , 2019, 79, 969-995.	10.9	49
52	ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 225.	8.6	83
53	An efficient or methodical review of immunotherapy against breast cancer. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22339.	3.0	14
54	Hibiscus flower extract selectively induces apoptosis in breast cancer cells and positively interacts with common chemotherapeutics. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 98.	3.7	44

#	ARTICLE	IF	CITATIONS
55	Treatment patterns, health care resource use and outcomes in metastatic triple-negative breast cancer in Germany: retrospective chart review study (OBTAIN). <i>Current Medical Research and Opinion</i> , 2019, 35, 1405-1414.	1.9	9
56	The Novel Mnk1/2 Degradar and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis. <i>Cancers</i> , 2019, 11, 299.	3.7	18
57	Induction of AMPK activation by N,N ^o -diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers. <i>PLoS ONE</i> , 2019, 14, e0209392.	2.5	16
58	Different mechanisms involved in the berberine ^o -induced antiproliferation effects in triple ^o -negative breast cancer cell lines. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13531-13544.	2.6	33
59	Metabolic Profiling of Amino Acids by Liquid Chromatography ^o -Tandem Mass Spectrometry (LC ^o -MS) to Characterize the Significance of Glutamine in Triple-Negative Breast Cancer (TNBC). <i>Analytical Letters</i> , 2019, 52, 1068-1082.	1.8	1
60	Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France. <i>BMC Cancer</i> , 2019, 19, 140.	2.6	7
61	The Design and Synthesis of Novel Phenothiazine Derivatives as Potential Cytotoxic Agents. <i>Letters in Drug Design and Discovery</i> , 2019, 17, 57-67.	0.7	4
62	Can we cure stage IV triple-negative breast carcinoma?. <i>Medicine (United States)</i> , 2019, 98, e17251.	1.0	5
63	LRP8 is overexpressed in estrogen ^o -negative breast cancers and a potential target for these tumors. <i>Cancer Medicine</i> , 2019, 8, 325-336.	2.8	18
64	Interplay between Epigenetics, Expression of Estrogen Receptor- ^o , HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy. <i>Cancers</i> , 2019, 11, 13.	3.7	22
65	Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. <i>Biochemical Pharmacology</i> , 2019, 159, 52-63.	4.4	52
66	FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 38.	2.4	25
67	Engineered Histidine-Enriched Facial Lipopeptides for Enhanced Intracellular Delivery of Functional siRNA to Triple Negative Breast Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 4719-4736.	8.0	20
68	Nanosoldiers: A promising strategy to combat triple negative breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 110, 319-341.	5.6	60
69	Pyroptosis: A new frontier in cancer. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109595.	5.6	574
70	Exosomes in triple negative breast cancer: Garbage disposals or Trojan horses?. <i>Cancer Letters</i> , 2020, 473, 90-97.	7.2	43
71	Quantitative proteomics discloses monacolin K-induced alterations in triple-negative breast cancer cell proteomes and phosphoproteomes. <i>Molecular Omics</i> , 2020, 16, 19-30.	2.8	2
72	Arylamide as Potential Selective Inhibitor for Matrix Metalloproteinase 9 (MMP9): Design, Synthesis, Biological Evaluation, and Molecular Modeling. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 349-359.	5.4	15

#	ARTICLE	IF	CITATIONS
73	Subtype specific targeting of calcium signaling in breast cancer. <i>Cell Calcium</i> , 2020, 85, 102109.	2.4	33
74	Nanoengineered Disruption of Heat Shock Protein 90 Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 5355-5366.	0.9	9
75	Targeting IL-3R α on tumor-derived endothelial cells blunts metastatic spread of triple-negative breast cancer via extracellular vesicle reprogramming. <i>Oncogenesis</i> , 2020, 9, 90.	4.9	30
76	Epigenetic Regulation and Dietary Control of Triple Negative Breast Cancer. <i>Frontiers in Nutrition</i> , 2020, 7, 159.	3.7	7
78	Effects of doxorubicin associated with amniotic membrane stem cells in the treatment of canine inflammatory breast carcinoma (IPC-366) cells. <i>BMC Veterinary Research</i> , 2020, 16, 353.	1.9	2
79	Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women. <i>Pharmaceuticals</i> , 2020, 13, 422.	3.8	14
80	Evaluation of chemotherapy and P2Et extract combination in ex-vivo derived tumor mammospheres from breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 19639.	3.3	11
81	Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14609-14625.	6.4	30
82	Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4. <i>Frontiers in Oncology</i> , 2020, 10, 1206.	2.8	21
83	Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 286.	4.4	13
84	Current trends and opportunities in targeting p21 activated kinase-1(PAK1) for therapeutic management of breast cancers. <i>Gene</i> , 2020, 760, 144991.	2.2	13
85	Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106125.	2.5	7
86	Maslinic acid differentially exploits the MAPK pathway in estrogen-positive and triple-negative breast cancer to induce mitochondrion-mediated, caspase-independent apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020, 25, 817-834.	4.9	16
87	Analysis of single-cell transcriptomes links enrichment of olfactory receptors with cancer cell differentiation status and prognosis. <i>Communications Biology</i> , 2020, 3, 506.	4.4	18
88	Pincerâ€¢Based Heterobimetallic Pt(II)/Ru(II), Pt(II)/Ir(III), and Pt(II)/Cu(I) Complexes: Synthesis and Evaluation of Antiproliferative Properties. <i>European Journal of Inorganic Chemistry</i> , 2020, 2020, 3370-3377.	2.0	10
89	Anti-Metastasis Fascin Inhibitors Decrease the Growth of Specific Subtypes of Cancers. <i>Cancers</i> , 2020, 12, 2287.	3.7	16
90	Can MRI Biomarkers Predict Triple-Negative Breast Cancer?. <i>Diagnostics</i> , 2020, 10, 1090.	2.6	22
91	Anti-metastatic action of an N4-aryl substituted thiosemicarbazone on advanced triple negative breast cancer.. <i>Heliyon</i> , 2020, 6, e05161.	3.2	0

#	ARTICLE	IF	CITATIONS
92	The effect of low frequency and low intensity ultrasound combined with microbubbles on the sonoporation efficiency of MDA-MB-231 cells. <i>Annals of Translational Medicine</i> , 2020, 8, 298-298.	1.7	8
93	Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer. <i>Redox Biology</i> , 2020, 34, 101564.	9.0	52
94	Extracellular vesicles produced by NFAT3-expressing cells hinder tumor growth and metastatic dissemination. <i>Scientific Reports</i> , 2020, 10, 8964.	3.3	9
95	Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. <i>Molecular Carcinogenesis</i> , 2020, 59, 1041-1051.	2.7	37
96	Targeted Heating of Mitochondria Greatly Augments Nanoparticle-Mediated Cancer Chemotherapy. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000181.	7.6	19
97	High triple-negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer. <i>Cancer</i> , 2020, 126, 2217-2224.	4.1	11
98	Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy. <i>Journal of Biological Chemistry</i> , 2020, 295, 6263-6277.	3.4	38
99	Moderate Exercise Modulates Tumor Metabolism of Triple-Negative Breast Cancer. <i>Cells</i> , 2020, 9, 628.	4.1	13
100	A Bis-Chelating / Ligand for the Synthesis of Heterobimetallic Platinum(II)/Rhenium(I) Complexes: Tools for the Optimization of a New Class of Platinum(II) Anticancer Agents. <i>Chemistry - A European Journal</i> , 2020, 26, 12846-12861.	3.3	14
101	Connexin 43 Modulates the Cellular Resistance to Paclitaxel via Targeting β -Tubulin in Triple-Negative Breast Cancer. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5323-5335.	2.0	6
102	Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 117-128.	3.6	41
103	Development of CAPER peptides for the treatment of triple negative breast cancer. <i>Cell Cycle</i> , 2020, 19, 432-447.	2.6	14
104	Reduction of nuclear Y654-catenin expression through SH3GL2-mediated downregulation of EGFR in chemotolerance TNBC: Clinical and prognostic importance. <i>Journal of Cellular Physiology</i> , 2020, 235, 8114-8128.	4.1	7
105	Krebs Cycle Intermediate-Modified Carbonate Apatite Nanoparticles Drastically Reduce Mouse Tumor Burden and Toxicity by Restricting Broad Tissue Distribution of Anticancer Drugs. <i>Cancers</i> , 2020, 12, 161.	3.7	6
106	Knockdown of A-kinase anchor protein 4 inhibits proliferation of triple-negative breast cancer cells in vitro and in vivo. <i>Tumor Biology</i> , 2020, 42, 101042832091447.	1.8	5
107	LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 31-41.	2.5	13
108	Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2078.	2.6	163
109	Hexane Extract of <i>Garcinia quaesita</i> Fruits Induces Apoptosis in Breast Cancer Stem Cells Isolated from Triple Negative Breast Cancer Cell Line MDA-MB-231. <i>Nutrition and Cancer</i> , 2021, 73, 845-855.	2.0	9

#	ARTICLE	IF	CITATIONS
110	Exosome vesicle as a nano-therapeutic carrier for breast cancer. Journal of Drug Targeting, 2021, 29, 121-130.	4.4	12
111	Vitamin D analogues exhibit antineoplastic activity in breast cancer patient-derived xenograft cells. Journal of Steroid Biochemistry and Molecular Biology, 2021, 208, 105735.	2.5	9
112	Cold atmospheric plasma modification of curcumin loaded in triphosphate chitosan nanoparticles enhanced breast cancer cells apoptosis. Polymers for Advanced Technologies, 2021, 32, 31-40.	3.2	8
113	Epigenetic Modulation of SPCA2 Reverses Epithelial to Mesenchymal Transition in Breast Cancer Cells. Cancers, 2021, 13, 259.	3.7	8
114	CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer. Computational and Structural Biotechnology Journal, 2021, 19, 2384-2397.	4.1	22
115	Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy. Cellular and Molecular Life Sciences, 2021, 78, 2105-2129.	5.4	13
116	The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin. Pathobiology, 2021, 88, 228-233.	3.8	9
117	Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells. Frontiers in Chemistry, 2020, 8, 602845.	3.6	8
118	Fluorouracil uptake in triple-negative breast cancer cells: Negligible contribution of equilibrative nucleoside transporters 1 and 2. Biopharmaceutics and Drug Disposition, 2021, 42, 85-93.	1.9	3
119	Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 2056.	4.1	10
120	USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer. Oncogenesis, 2021, 10, 28.	4.9	13
121	Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy. Scientific Reports, 2021, 11, 7259.	3.3	20
122	Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129841.	2.4	24
123	Epoxyazadiradione induced apoptosis/anoikis in triple-negative breast cancer cells, MDA-MB-231, by modulating diverse cellular effects. Journal of Biochemical and Molecular Toxicology, 2021, 35, 1-17.	3.0	11
124	New Insight into Triple-Negative Breast Cancer Therapy: The Potential Roles of Endoplasmic Reticulum Stress and Autophagy Mechanisms. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 679-691.	1.7	3
125	An <i>in vitro</i> study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells. Journal of Pharmacy and Pharmacology, 2021, 73, 749-757.	2.4	13
126	HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models. Cancers, 2021, 13, 2007.	3.7	11
127	Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy. PLoS ONE, 2021, 16, e0250453.	2.5	12

#	ARTICLE	IF	CITATIONS
128	Role of AMPK and Akt in triple negative breast cancer lung colonization. <i>Neoplasia</i> , 2021, 23, 429-438.	5.3	5
129	Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines. <i>Molecular Biology Reports</i> , 2021, 48, 3439-3449.	2.3	12
130	Cholesterol-Induced Metabolic Reprogramming in Breast Cancer Cells Is Mediated via the ERR α Pathway. <i>Cancers</i> , 2021, 13, 2605.	3.7	13
131	Nanodiamonds and their potential applications in breast cancer therapy: a narrative review. <i>Drug Delivery and Translational Research</i> , 2022, 12, 1017-1028.	5.8	7
132	Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins. <i>Frontiers in Oncology</i> , 2021, 11, 656687.	2.8	18
133	Real-World Clinical Outcomes in Biological Subgroups of Breast Cancer in the Hospital District of Southwest Finland. <i>Oncologist</i> , 2021, 26, e1372-e1380.	3.7	6
134	Cytoprotective Effect of Vitamin D on Doxorubicin-Induced Cardiac Toxicity in Triple Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7439.	4.1	11
135	DIF-1 inhibits growth and metastasis of triple-negative breast cancer through AMPK-mediated inhibition of the mTORC1-S6K signaling pathway. <i>Oncogene</i> , 2021, 40, 5579-5589.	5.9	18
136	A new immunochemical strategy for triple-negative breast cancer therapy. <i>Scientific Reports</i> , 2021, 11, 14875.	3.3	6
137	Systems Pharmacology-Based Precision Therapy and Drug Combination Discovery for Breast Cancer. <i>Cancers</i> , 2021, 13, 3586.	3.7	4
138	Prevalence and Mortality of Triple-Negative Breast Cancer in West Africa: Biologic and Sociocultural Factors. <i>JCO Global Oncology</i> , 2021, 7, 1129-1140.	1.8	11
139	Association of statin use with clinical outcomes in patients with triple-negative breast cancer. <i>Cancer</i> , 2021, 127, 4142-4150.	4.1	22
140	Triple-negative breast cancer: understanding Wnt signaling in drug resistance. <i>Cancer Cell International</i> , 2021, 21, 419.	4.1	40
141	[(Câ€‰Au(Nâ€‰)] ⁺ Complexes as a New Family of Anticancer Candidates: Synthesis, Characterization and Exploration of the Antiproliferative Properties. <i>Chemistry - A European Journal</i> , 2021, 27, 15773-15785.	3.3	11
142	New functionalized 6â€‰thienylpyrimidineâ€‰carbonitriles as antiproliferative agents against human breast cancer cells. <i>Archiv Der Pharmazie</i> , 2021, 354, e2100177.	4.1	5
143	Production and Evaluation of In-vitro and In-vivo Effects of P28-IL24, a Promising Anti-breast Cancer Fusion Protein. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 2583-2594.	1.9	1
144	Hormone-Dependent Tumors and Sexuality in the Neuro-Oncology of Women (N.O.W.): Women's Brain Tumors, Gaps in Sexuality Considerations, and a Need for Evidence-Based Guidelines. <i>Current Oncology Reports</i> , 2021, 23, 127.	4.0	3
145	Curcumin-cinnamaldehyde hybrids as antiproliferative agents against women's cancer cells. <i>Medicinal Chemistry Research</i> , 0, , 1.	2.4	0

#	ARTICLE	IF	CITATIONS
146	Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer. <i>Materials Today</i> , 2021, 50, 149-169.	14.2	33
148	Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning. <i>Journal of Personalized Medicine</i> , 2021, 11, 881.	2.5	5
149	The Role of Non-Coding RNAs in Breast Cancer Drug Resistance. <i>Frontiers in Oncology</i> , 2021, 11, 702082.	2.8	11
150	Breast cancer stem cells: A review of their characteristics and the agents that affect them. <i>Molecular Carcinogenesis</i> , 2021, 60, 73-100.	2.7	28
151	Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer. <i>Journal of Controlled Release</i> , 2020, 323, 549-564.	9.9	13
153	The triacylglycerol, hydroxytrirolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt. <i>Oncotarget</i> , 2019, 10, 2486-2507.	1.8	15
154	Long non-coding RNAs regulation of therapeutic resistance. , 2019, 2, 550-567.		1
155	Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer. <i>Current Cancer Drug Targets</i> , 2020, 20, 559-572.	1.6	14
156	Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients). <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 3581-3589.	1.2	8
157	Apoptotic Resistance of Metastatic Tumor Cells in Triple Negative Breast Cancer: Roles of Death Receptor-5. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 1743-1748.	1.2	10
158	IL-6 Impairs the Activity of Vitamin D3 in the Regulation of Epithelial-Mesenchymal Transition in Triple Negative Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2267-2273.	1.2	2
159	Synergistic Induction of Apoptosis by the Combination of an Axl Inhibitor and Auranofin in Human Breast Cancer Cells. <i>Biomolecules and Therapeutics</i> , 2020, 28, 473-481.	2.4	12
160	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1096-1104.	4.9	33
161	Crystallization of the Multi-Receptor Tyrosine Kinase Inhibitor Sorafenib for Controlled Long-Term Drug Delivery Following a Single Injection. <i>Cellular and Molecular Bioengineering</i> , 2021, 14, 471-486.	2.1	0
164	Androgen Receptor Expression and Its Correlation with Clinicopathological Parameters in Iranian Patients with Triple Negative Breast Cancer. <i>Iranian Journal of Pathology</i> , 2020, 15, 239-244.	0.5	2
166	Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4. <i>Pharmaceuticals</i> , 2021, 14, 1119.	3.8	7
167	Chick Embryo Experimental Platform for Micrometastases Research in a 3D Tissue Engineering Model: Cancer Biology, Drug Development, and Nanotechnology Applications. <i>Biomedicines</i> , 2021, 9, 1578.	3.2	2
168	An Insight into the Role of Bee Venom and Melittin Against Tumor Cells: A Review of Breast Cancer therapy. <i>Archives of Breast Cancer</i> , 0, , 267-276.	0.5	1

#	ARTICLE	IF	CITATIONS
169	Cancer-associated fibroblast-derived LRRC15 promotes the migration and invasion of triple-negative breast cancer cells via Wnt/ β 2-catenin signalling pathway regulation. <i>Molecular Medicine Reports</i> , 2021, 25, .	2.4	11
170	The Cytotoxicity of RNase-Derived Peptides. <i>Biomolecules</i> , 2021, 11, 16.	4.0	6
171	Pharmacologic Modulation of the Immune Response Against Tumours in the Elderly. , 2020, , 157-164.		0
173	Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence. <i>Expert Review of Vaccines</i> , 2022, 21, 337-353.	4.4	9
174	Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 15-24.	1.8	15
175	Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA. <i>Cancers</i> , 2022, 14, 248.	3.7	3
176	Construction and Validation of a Prognostic Risk Model for Triple-Negative Breast Cancer Based on Autophagy-Related Genes. <i>Frontiers in Oncology</i> , 2022, 12, 829045.	2.8	11
177	CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 989.	3.7	8
178	Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6. <i>Npj Breast Cancer</i> , 2022, 8, 30.	5.2	14
179	Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 2909-2918.	1.7	0
180	Nm23-H1 activator phenylbutenoid dimer exerts cytotoxic effects on metastatic breast cancer cells by inducing mitochondrial dysfunction only under glucose starvation. <i>Scientific Reports</i> , 2021, 11, 23549.	3.3	3
181	Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer. <i>Molecules</i> , 2021, 26, 7654.	3.8	11
196	Alpha-mangostin as an inhibitor of GSK3 β in triple-negative breast cancer. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 4515-4521.	3.5	2
197	Receptor-Targeted Surface-Engineered Nanomaterials for Breast Cancer Imaging and Theranostic Applications. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2022, 39, 1-44.	2.2	14
198	Different drug delivery approaches in combinational therapy in TNBC. , 2022, , 201-230.		6
199	Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report. <i>Case Reports in Oncology</i> , 2022, 15, 473-479.	0.7	7
200	Three-Dimensional Organotypic Cultures Reshape the microRNAs Transcriptional Program in Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 2490.	3.7	6
201	Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells. <i>Nutrients</i> , 2022, 14, 2120.	4.1	6

#	ARTICLE	IF	CITATIONS
202	Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	0
203	The combined restoration of miR-424-5p and miR-142-3p effectively inhibits MCF-7 breast cancer cell line via modulating apoptosis, proliferation, colony formation, cell cycle and autophagy. <i>Molecular Biology Reports</i> , 2022, 49, 8325-8335.	2.3	8
204	Cytotoxic and antiparasitic activities of diphosphine-metal complexes of group 10 containing acylthiourea as ligands. <i>Journal of Inorganic Biochemistry</i> , 2022, 234, 111906.	3.5	4
205	Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	3
206	Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment. <i>Pharmaceuticals</i> , 2022, 15, 881.	3.8	10
207	Vitamin D: an essential adjuvant therapeutic agent in breast cancer. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211138.	1.0	3
209	Interleukin-3-Receptor- α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target. <i>Cancers</i> , 2022, 14, 3918.	3.7	6
210	Evaluation of anticancer effects of frankincense on breast cancer stem-like cells. <i>Cancer Reports</i> , 0, , .	1.4	3
211	Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α /miR-494/Survivin signaling pathway. <i>Neoplasia</i> , 2022, 32, 100821.	5.3	16
212	Oncogenic and Stemness Signatures of the High-Risk HCMV Strains in Breast Cancer Progression. <i>Cancers</i> , 2022, 14, 4271.	3.7	10
213	The Effect of Neoadjuvant vs Adjuvant Chemotherapy on Final Outcome of Patients with Triple Negative Breast Cancer. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , .	0.9	1
214	Simvastatine. <i>Medecine/Sciences</i> , 2022, 38, 646-647.	0.2	0
215	Ligand-Specific Nano-Contrast Agents Promote Enhanced Breast Cancer CT Detection at 0.5 mg Au. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9926.	4.1	2
216	Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10119.	4.1	2
217	Chemotherapeutic Protocols for the Treatment of Breast Cancer. , 2022, , 79-123.		0
219	Synthesis and Structure-Activity Relationship Studies of Novel Aryl Sulfonamides and Their Activity against Human Breast Cancer Cell Lines. <i>Chemistry and Biodiversity</i> , 2022, 19, .	2.1	0
220	Targeting Triple Negative Breast Cancer Stem Cells by Heat Shock Protein 70 Inhibitors. <i>Cancers</i> , 2022, 14, 4898.	3.7	5
221	Unique therapeutic potentialities of exosomes based nanodrug carriers to target tumor microenvironment in cancer therapy. <i>OpenNano</i> , 2022, 8, 100091.	4.8	8

#	ARTICLE	IF	CITATIONS
222	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
223	New tricyclic systems as photosensitizers towards triple negative breast cancer cells. <i>Archives of Pharmacal Research</i> , 2022, 45, 806-821.	6.3	16
224	Therapeutic significance of molecular hybrids for breast cancer research and treatment. <i>RSC Medicinal Chemistry</i> , 0, , .	3.9	3
225	High percentage of Cancer Stem cells in metastatic locations: Upregulation of cicBIRC6 in highly metastatic breast Cancer Subline. <i>Molecular Biology Reports</i> , 2023, 50, 1303-1309.	2.3	2
226	In Vitro Self-Assembly of a Modified Diphenylalanine Peptide to Nanofibers Induced by the Eye Absent Enzyme and Alkaline Phosphatase and Its Activity against Breast Cancer Cell Proliferation. <i>ACS Applied Bio Materials</i> , 2023, 6, 164-170.	4.6	2
227	Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. <i>Cancers</i> , 2023, 15, 403.	3.7	3
229	Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer. <i>Bioorganic Chemistry</i> , 2023, 134, 106437.	4.1	5
230	Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs. <i>Journal of Medical Economics</i> , 2023, 26, 254-261.	2.1	4
231	Discovery of aminothiazole derivatives as a chemical scaffold for glutaminase inhibition. <i>Results in Chemistry</i> , 2023, 5, 100842.	2.0	0
232	Radiosensitization of Breast Cancer Cells with a 2-Methoxyestradiol Analogue Affects DNA Damage and Repair Signaling In Vitro. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3592.	4.1	0
233	A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. <i>Journal of Advanced Research</i> , 2023, 54, 271-292.	9.5	15
234	Critical Review on the Different Roles of Exosomes in TNBC and Exosomal-Mediated Delivery of microRNA/siRNA/lncRNA and Drug Targeting Signalling Pathways in Triple-Negative Breast Cancer. <i>Molecules</i> , 2023, 28, 1802.	3.8	2
235	Proteomic profiling and ROC analysis identify CD151 and ELAVL1 as potential therapy response markers for the antiviral drug in resistant TNBC. <i>Life Sciences</i> , 2023, 320, 121534.	4.3	1
236	S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720. <i>Cells</i> , 2023, 12, 980.	4.1	2
237	Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple negative breast cancer. <i>Journal of Biomolecular Structure and Dynamics</i> , 2024, 42, 1099-1109.	3.5	7
238	An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	2
239	Regulation of ER α -dependent breast cancer metastasis by a miR-29a signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	8.6	3
240	Characterization of clinicopathological features, treatment practices, and outcomes among Finnish advanced breast cancer patients in real-life clinical practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 9139-9149.	2.5	1

#	ARTICLE	IF	CITATIONS
241	Structure-based virtual screening for identification of potential CDC20 inhibitors and their therapeutic evaluation in breast cancer. 3 Biotech, 2023, 13, .	2.2	1
242	Antiproliferative effects of 13 β -steroids on triple-negative MDA-MB-231 breast cancer cells: unraveling intracellular signaling without ER α . Brazilian Journal of Pharmaceutical Sciences, 0, 59, .	1.2	1
243	Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors. Breast Cancer Research, 2023, 25, .	5.0	1
244	In-silico Elucidation of the Role of ABC-Transporter Genes Expression Regulation by OncomiRs (miR-21,) Tj ETQq1 1 0.784314 rgBT /Ove Bioinformatics, 2023, 18, 128-144.	0.6	1
245	Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Research Communications, 2023, 3, 1078-1092.	1.7	2
246	Metastatic Triple-Negative Breast Cancer. Current Breast Cancer Reports, 0, , .	1.0	0
247	Breast cancer brain metastasis: from etiology to state-of-the-art modeling. Journal of Biological Engineering, 2023, 17, .	4.7	4
248	Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials. Cancer Cell International, 2023, 23, .	4.1	4
249	Cell membrane-cloaked bioinspired nanoparticles: a novel strategy for breast cancer therapy. Journal of Dispersion Science and Technology, 0, , 1-13.	2.4	0
250	Theranostics of triple negative breast cancer: a review. Diagnostic Radiology and Radiotherapy, 2023, 14, 15-30.	0.2	0
251	Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens. Frontiers in Oncology, 0, 13, .	2.8	3
252	Prox1 Suppresses the Proliferation of Breast Cancer Cells via Direct Inhibition of c-Myc Gene Expression. Cells, 2023, 12, 1869.	4.1	0
253	Small EV in plasma of triple negative breast cancer patients induce intrinsic apoptosis in activated T cells. Communications Biology, 2023, 6, .	4.4	1
254	Synthesis, anticancer activity and molecular modeling study of novel substituted triazole linked tetrafluoronaphthalene hybrid derivatives. Journal of Biomolecular Structure and Dynamics, 0, , 1-20.	3.5	2
255	Targeting NKG2DL with Bispecific NKG2D α -CD16 and NKG2D α -CD3 Fusion Proteins on Triple α -Negative Breast Cancer. International Journal of Molecular Sciences, 2023, 24, 13156.	4.1	0
256	Novel Strategies Using Sagacious Targeting for Site-Specific Drug Delivery in Breast Cancer Treatment: Clinical Potential and Applications. Critical Reviews in Therapeutic Drug Carrier Systems, 2024, 41, 35-84.	2.2	0
257	Anti-cancer effect of a phytochemical compound α -7R-acetylmelodorinol α against triple-negative breast cancer cells. Biomedicine and Pharmacotherapy, 2023, 166, 115286.	5.6	2
258	Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis. BMC Cancer, 2023, 23, .	2.6	2

#	ARTICLE	IF	CITATIONS
259	Identification of TUBB2A as a Cancer-Immunity Cycle-Related Therapeutic Target in Triple-Negative Breast Cancer. <i>Molecular Biotechnology</i> , 0, , .	2.4	0
260	Adoption and use of immunotherapy in breast cancer management in Africa; barriers and prospect- a narrative review. <i>Annals of Medicine and Surgery</i> , 0, , .	1.1	0
261	Hydroxypropyl- β -cyclodextrin inhibits the development of triple negative breast cancer by enhancing antitumor immunity. <i>International Immunopharmacology</i> , 2023, 125, 111168.	3.8	1
262	Locally Advanced Adenoid Cystic Carcinoma of the Breastâ€”A Case Report with a Review of the Literature. <i>Medicina (Lithuania)</i> , 2023, 59, 2005.	2.0	0
263	<i>In vitro</i> anticancer evaluation of Enceamycin A and its underlying mechanism. <i>RSC Advances</i> , 2023, 13, 34183-34193.	3.6	0
264	Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland. <i>PharmacoEconomics - Open</i> , 0, , .	1.8	1
265	Risk factors and survival of tripleâ€”negative breast cancer among breast cancer patients: Tenâ€”year crossâ€”sectional study in the southwestern Iranian population. <i>Health Science Reports</i> , 2023, 6, .	1.5	0
266	Exploring the Regulatory Roles of miR-21, miR-15, and miR-let-7 in ABC Transporter-Mediated Chemo-resistance: Implications for Breast Cancer Etiology and Treatment. <i>Molecular Biotechnology</i> , 0, , .	2.4	0
267	Comparative efficacy of silver alginate dressings versus standard gauze in enhancing wound healing <scp>postâ€”mastectomy</scp> for <scp>tripleâ€”negative</scp> breast cancer: A systematic review and <scp>metaâ€”analysis</scp>. <i>International Wound Journal</i> , 0, , .	2.9	0
268	Role of Epigenetics for the Efficacy of Cisplatin. <i>International Journal of Molecular Sciences</i> , 2024, 25, 1130.	4.1	1
270	Short peptides based on the conserved regions of MIEN1 protein exhibit anticancer activity by targeting the MIEN1 signaling pathway. <i>Journal of Biological Chemistry</i> , 2024, 300, 105680.	3.4	0
271	Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer. <i>Journal of Drug Delivery Science and Technology</i> , 2024, 93, 105401.	3.0	0
272	Multifaceted antineoplastic curative potency of novel water-soluble methylimidazole-based oxidovanadium (IV) complex against triple negative mammary carcinoma. <i>Cellular Signalling</i> , 2024, 117, 111089.	3.6	0
273	Zinc oxide-manganese oxide/carboxymethyl cellulose-folic acid-sesamol hybrid nanomaterials: A molecularly targeted strategy for advanced triple-negative breast cancer therapy. <i>Green Processing and Synthesis</i> , 2024, 13, .	3.4	0
274	MLL1 regulates cytokine-driven cell migration and metastasis. <i>Science Advances</i> , 2024, 10, .	10.3	0
275	Context-Responsive Nanoparticle Derived from Synthetic Zwitterionic Ionizable Phospholipids in Targeted CRISPR/Cas9 Therapy for Basal-like Breast Cancer. <i>ACS Nano</i> , 2024, 18, 9199-9220.	14.6	0